Compare HFWA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | MRVI |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1997 | 2020 |
| Metric | HFWA | MRVI |
|---|---|---|
| Price | $29.06 | $8.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $30.50 | $4.13 |
| AVG Volume (30 Days) | 342.7K | ★ 3.5M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 58.06 | 14.29 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $45.85 | $12.54 |
| Revenue Next Year | $7.83 | $7.87 |
| P/E Ratio | $32.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.32 | $2.29 |
| 52 Week High | $31.25 | $8.87 |
| Indicator | HFWA | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 73.77 |
| Support Level | $28.94 | $3.27 |
| Resistance Level | $30.36 | N/A |
| Average True Range (ATR) | 0.48 | 0.46 |
| MACD | -0.11 | 0.26 |
| Stochastic Oscillator | 31.02 | 85.40 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.